Previous 10 | Next 10 |
2023-07-31 08:46:52 ET Checkpoint Therapeutics ( NASDAQ: CKPT ) has entered into a definitive agreement for the issuance and sale of an aggregate of ~3.24M shares of its common stock, ~3.24M of Series A and B warrants to purchase up to 3.2M shares, at a purchase price of $3.09...
2023-07-31 08:19:22 ET Checkpoint Therapeutics ( CKPT ) -14% announces $10 Million registered direct offering priced at-the-market. Citius Pharmaceuticals ( CTXR ) -13% . BioNexus Gene Lab Corp. ( BGLC ) -13% . Blue Star Foods Corp. ( BSFC ) -...
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3...
2023-07-30 04:19:15 ET Summary Checkpoint Therapeutics announced updated, longer-term data for cosibelimab from their pivotal trial in locally advanced and metastatic cutaneous squamous cell carcinoma “cSCC”. The data revealed improved response over time with higher ...
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a favorable safety profile Biologics License Application currently under review ...
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 WALTHAM, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Checkpoint T...
2023-05-23 16:08:48 ET Checkpoint Therapeutics ( NASDAQ: CKPT ) said Tuesday it has priced the offering of common stock and warrants to raise $10 million. The company will offer 3,256,269 shares of its common stock or pre-funded warrants in lieu thereof, Series A warrants to p...
WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,...
2023-05-21 10:03:52 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re a risk taker on the lookout for stocks with 1000% upside potential, you’d have to venture into speculative territory. It is difficult to find analyst ratings with such...
2023-05-15 16:58:49 ET Checkpoint Therapeutics press release ( NASDAQ: CKPT ): Q1 GAAP EPS of -$0.89. For further details see: Checkpoint Therapeutics GAAP EPS of -$0.89
News, Short Squeeze, Breakout and More Instantly...
Checkpoint Therapeutics Inc. Company Name:
CKPT Stock Symbol:
NASDAQ Market:
Checkpoint Therapeutics Inc. Website:
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the resubmission of its Biologics License Application (“BLA”) t...